drugset / Trial / NCT01119794
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
Phase 2
Terminated
10 enrolled
Brown University
Dartmouth-Hitchcock Medical Center · collabMemorial Hospital of Rhode Island · collabRhode Island Hospital · collabThe Miriam Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to: Investigate the Overall Response Rate (ORR) of the combination of ofatumumab and bortezomib in patients with low-grade B-cell non-Hodgkin lymphoma (LG-NHL) that relapse beyond 6 months of a previous rituximab-containing regimen.
Timeline
- Start
- 2010-07
- Primary completion
- 2015-07
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.6 mg/m2 | Intravenous |
| Subject | Ofatumumab | Monoclonal antibody | 1000 mg | Intravenous |